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OBJECTIVES This study was an analysis of factors associated with stroke in a population of patients paced
for sinus node dysfunction in a large prospective clinical trial (Mode Selection Trial
[MOST]).
BACKGROUND The effects of dual-chamber versus single-chamber ventricular pacing on subsequent stroke in
patients with sinus node dysfunction are not known.
METHODS A total of 2,010 patients with sinus node dysfunction were randomized to ventricular or
dual-chamber pacing and followed for a median of 33.1 months.
RESULTS The median participant age was 74 years. During 5,664 patient-years of follow-up, 90 strokes
(11 hemorrhagic) occurred. By life-table analysis, the rate of stroke was 2.2% (95% confidence
interval [CI] 1.6 to 2.9) at one year and 5.8% (95% CI 4.5 to 7.1) at four years. The incidence
of stroke was not significantly different in dual-chamber (4%) as compared with ventricular-
paced patients (4.9%) (hazard ratio [HR] 0.82, 95% CI 0.54 to 1.25, p 0.36). Multivariable
analysis demonstrated that significant predictors of stroke included prior stroke or transient
ischemic attack, Caucasian race, hypertension, prior systemic embolism, and New York Heart
Association functional class III or IV (p 0.05); pacing mode remained non-significant after
adjustment for these factors (p  0.37). Clinically reported atrial fibrillation after implanta-
tion was a risk factor for stroke in this cohort after adjustment for other predictors of stroke
(p  0.042, HR 1.68 [95% CI 1.02 to 2.76]).
CONCLUSIONS Clinical characteristics, but not mode of pacing, were associated with subsequent stroke in
patients paced for sinus node dysfunction. (J Am Coll Cardiol 2004;43:1617–22) © 2004
by the American College of Cardiology Foundationa
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2he most common indication for implantation of a perma-
ent pacemaker is sick sinus syndrome (1). It is estimated
hat the yearly incidence of stroke in this population is
pproximately 6% to 10% (2–7). Several large randomized
See page 1623
linical trials have established that atrial fibrillation (AF),
hich commonly occurs in patients with sinus node dys-
unction (8,9), is associated with an annual risk of stroke of
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Manuscript received May 5, 2003; revised manuscript received August 19, 2003,mccepted September 24, 2003.pproximately 5%, which may be significantly lowered to
.7% with appropriate anticoagulant therapy (10). Previous
rials have suggested that physiologic pacing may decrease
he incidence of AF (11–14). Although there is a direct
elationship between AF and stroke, the effects of physio-
ogic pacing on stroke are less clear (11–16). The Mode
election Trial (MOST) was a large, prospective, random-
zed, clinical trial designed to analyze the role of physiologic
acing on the outcome of patients receiving a pacemaker for
ymptomatic sick sinus syndrome (15). The present study is
n analysis of factors associated with stroke in this patient
opulation.
ETHODS
tudy design. The MOST study was designed as a five-
ear trial to compare ventricular rate-modulated (VVIR)
acing with dual-chamber rate-modulated pacing (DDDR)
n patients whose sinus node dysfunction required perma-
ent pacing for bradycardia (15). The first patient was
nrolled on September 25, 1995, and the last patient on
ctober 13, 1999. Follow-up ended January 31, 2001. The
,010 enrolled patients at 91 clinical sites (Appendix) had a
edian follow-up of 33.1 months.
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Stroke in Patients Paced for Sick Sinus Syndrome May 5, 2004:1617–22The design of the study has been described (17). In brief,
atients with documented sinus node dysfunction undergo-
ng implantation of a dual-chamber pacing system were
ligible for admission into the trial if they were age 21 years
r older, were in sinus rhythm at the time of randomization,
nd had adequate atrial and ventricular sensing and pacing
hresholds. Before implantation, all patients had a clinical
ssessment including history and physical examination,
aseline New York Heart Association (NYHA) functional
lass for heart failure, a mini-mental state examination (18),
nd a quality-of-life evaluation that included the 36-item
edical Outcomes Study Short-form General Health Sur-
ey (19). Comorbidities were assessed with the Charlson
omorbidity Index (20). The site investigators recorded
istory of prior stroke or transient ischemic attack (TIA).
All patients received a DDDR pacemaker. Pacing mode
as then randomly assigned to either VVIR or DDDR
acing by the Data Coordinating Center at the Duke
linical Research Institute. Randomization was stratified by
istory of stroke and by clinical site.
Following implantation, all patients were seen at a clinical
ite four times during the first year and then twice yearly
hereafter. A complete history and physical examination,
ncluding neurologic evaluation, were performed at each
ollow-up visit. If a stroke was suspected, the clinical center
as required to consult a local neurologist who would then
btain a brain imaging study (either computerized tomog-
aphy or magnetic resonance imaging). The clinical site
eurologist was responsible for documenting the clinical
nd laboratory findings of the stroke on a separate case
eport form. Events were classified on the basis of case
eport forms, hospital records, and brain imaging. On the
asis of these findings the stroke was characterized as
rimary hemorrhagic, ischemic, or unknown. Hemorrhagic
trokes were subclassified as intraparenchymal, subarach-
oid hemorrhage, or subdural hematoma. A clinical events
ommittee composed of six cardiologists and two neurolo-
ists classified the cause of death and adjudicated all
uspected strokes unaware of the mode of pacing. Atrial
brillation was adjudicated by an electrocardiographic core
ab.
Warfarin use data from the follow-up period were used to
etermine whether patients were taking warfarin during any
f the following time periods: at hospital discharge, during
Abbreviations and Acronyms
AF  atrial fibrillation
CI  confidence interval
CTOPP  Canadian Trial Of Physiologic Pacing
DDDR  dual-chamber rate-modulated
MOST  Mode Selection Trial
NYHA  New York Heart Association
TIA  transient ischemic attack
VVIR  ventricular rate-modulatedhe first year, during the second year, or after the second rear. Limitations of medication use data precluded any finer
haracterization of warfarin use patterns.
tatistical analysis. The two pacing mode groups were
nalyzed on an intention-to-treat basis. Cumulative event
ates were calculated by the Kaplan-Meier (21) method.
ingle-predictor Cox proportional hazards models (22)
ere used to assess the relationship of baseline variables to
troke in univariable analyses. Multivariable analysis of
aseline factors, in which all variables were considered
imultaneously for their relationship to stroke, also used a
ox proportional hazards model with time to first stroke as
he outcome variable. Cox models for the association of
ost-randomization AF with stroke included AF as a
ime-dependent covariate, which allows patients to move
rom the no-AF risk class to the AF risk class at the first
ocumented occurrence of AF. To assess the role of
otential predictors of stroke without the possible con-
ounding effect of warfarin use, univariable and multivari-
ble analyses were also performed in the subgroup of 1,204
atients who did not receive warfarin at any time.
To assess the relationship between AF and subsequent
arfarin use and, therefore, the extent to which warfarin use
ight affect the AF-stroke risk relationship, we used unad-
usted logistic regression models to examine the association
f AF in the first year post-randomization with warfarin use
n the second year among patients with no warfarin use in
he first year.
ESULTS
emographics. The 2,010 patients who were entered into
he trial had a median age of 74 years (interquartile range of
8 to 80 years). Of these, 996 patients were randomized to
VIR pacing and 1,014 were randomized to DDDR
acing. Baseline characteristics and cardiac risk factors,
ncluding age, female gender (VVIR  48% vs. DDDR 
7%), and minority race (VVIR 14% vs. DDDR 16%),
ere similar in both groups (Table 1). The prevalence of
isk factors for stroke, such as hypertension (VVIR  61%
s. DDDR  63%), hypercholesterolemia (VVIR  34%
s. DDDR  37%), cigarette smoking (VVIR  9% vs.
DDR  8%), and diabetes mellitus (VVIR  20% vs.
DDR  24%), was also similar in the two groups.
lthough a slight imbalance existed in other clinical vari-
bles favoring less sick patients in the VVIR pacing group,
e used multivariable analyses to control for these differ-
nces. Of those patients who had a history of AF or flutter,
6% had their most recent episode within the three weeks
efore randomization.
A prior stroke was reported in 11% (n  108) of the
VIR pacing patients and 11% (n  116) of the DDDR
acing patients. The median time since the most recent
troke was similar in both groups (VVIR  2.4 years
interquartile range 0.4 to 7.6] vs. DDDR  2.3 years
interquartile range 0.6 to 6.0]). A previous TIA was
eported in 8% (n 77) of VVIR pacing patients and 7% (n

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May 5, 2004:1617–22 Stroke in Patients Paced for Sick Sinus Syndrome66) of DDDR pacing patients. The median time since
he most recent TIA was also similar in both groups (VVIR
0.9 years [interquartile range 0.0 to 2.9] vs. DDDR 1.5
ears [interquartile range 0.0 to 4.2]). Prior systemic embo-
ism was also similar in the two groups (VVIR  3%, n 
6 vs. DDDR  3%, n  30).
linical events. Patients were followed for a median of
3.1 months (interquartile range 21.4 to 46.3 months),
hich represents 5,664 patient-years of follow-up. Over the
ourse of the trial, there were 90 strokes (Table 2). The
ne-year, three-year, and four-year event rates in the
OST study were 2.2% (95% confidence interval [CI] 1.6
o 2.9), 4.9% (95% CI 3.8 to 6.0), and 5.8% (95% CI 4.5 to
.1), respectively. There were 49 strokes (4.9%) in the
VIR pacing group versus 41 in the DDDR pacing group
4%) (unadjusted hazard ratio [HR] for DDDR:VVIR 
.82 [95% CI 0.54 to 1.25], p  0.36) (Fig. 1). Two
atients had more than one stroke in the VVIR pacing
roup as compared with six patients in the DDDR pacing
roup. There was no difference in the type of stroke
ecorded in each group. Most strokes were due to ischemia
VVIR  88%, n  43 vs. DDDR  78%, n  32) as
pposed to hemorrhage (VVIR 10%, n 5 vs. DDDR
5%, n  6).
able 1. Baseline Clinical Characteristics
Ventricular
(n  996)
Dual-Chamber
(n  1,014)
p
Value
eneral characteristics
Age 74 (68, 80) 74 (67, 80) 0.58
Female gender 48% (477) 47% (478) 0.74
Minority race 14% (144) 16% (162) 0.34
ardiac risk factors
Hypertension 61% (608) 63% (640) 0.34
Hypercholesterolemia 34% (340) 37% (376) 0.17
Cigarette smoking 9% (85) 8% (84) 0.87
Diabetes 20% (204) 24% (246) 0.042
ardiac history
Previous MI 24% (243) 28% (279) 0.11
Prior CHF 18% (183) 22% (221) 0.054
NYHA functional class I or II 85% (841) 82% (822) 0.049
Atrial fibrillation or flutter 44% (440) 47% (477) 0.20
ontinuous variables are presented as median (25th, 75th percentile). Categorical
ariables are presented as % (n).
CHF  congestive heart failure; MI  myocardial infarction; NYHA  New
ork Heart Association.
able 2. Cerebrovascular Events
VVIR DDDR
resence of stroke 4.9% (49) 4.0% (41)
atients with more than one stroke 2 6
rimary hemorrhagic 10.2% (5) 14.6% (6)
Intraparenchymal subarachnoid
hemorrhage
80.0% (4) 33.3% (2)
Subdural hematoma 20.0% (1) 66.7% (4)
schemic stroke 87.8% (43) 78% (32)
nknown 2.0% (1) 7.3% (3)
ata are presented as % (n).
DDDR  dual-chamber rate-modulated pacing; VVIR  ventricular rate-dodulated pacing.nivariable analysis. Prior stroke, prior TIA, prior neuro-
ogic event (either stroke or TIA), prior systemic embolism,
ge, hypertension, and NYHA functional class were asso-
iated with subsequent stroke (p  0.05). Twenty other
aseline variables were not found to be associated with
troke, including neurologic deficit on baseline physical
xamination, gender, weight, race, diabetes, prior myocar-
ial infarction, history of congestive heart failure or AF,
herapy with aspirin or coumadin at admission, antiarrhyth-
ic drug therapy, and pacing mode. A history of AF was
ot a predictor of subsequent stroke (p  0.22).
ultivariable analysis. A multivariable analysis of baseline
actors as predictors of subsequent stroke was performed
hen all variables were considered simultaneously (Table 3).
ignificant predictors included prior stroke or TIA (p 
.014, HR 1.80 [95% CI 1.12 to 2.89]), Caucasian race (p
0.024, HR 2.44 [95% CI 1.12 to 5.32]), hypertension (p
0.028, HR 1.70 [95% CI 1.06 to 2.72]), prior systemic
mbolism (p 0.037, HR 2.43 [95% CI 1.06 to 5.60]), and
YHA chronic heart failure functional class III or IV (p 
.044, HR 1.67 [95% CI 1.01 to 2.77]). Atrial fibrillation
ollowing randomization was a significant risk factor for
troke (p  0.042, HR 1.68 [95% CI 1.02 to 2.76]) after
djustment for other significant predictors of stroke. Pacing
ode was not predictive of subsequent stroke (p  0.37).
arfarin and aspirin. At the time of hospital discharge
fter pacemaker implantation, approximately one-half of the
atients in the trial were taking aspirin (VVIR  46%, n 
58 vs. DDDR 49%, n 496) whereas 23% of the VVIR
acing group (n  233) and 24% of the DDDR pacing
roup (n  238) were taking warfarin. Therefore, approx-
mately three-quarters of the patients in the MOST study
ere taking either aspirin or warfarin immediately after
mplantation.
Neither warfarin (p  0.5) nor aspirin use (p  0.2) at
ospital admission was a negative risk factor for stroke. In
he MOST study, 773 patients were taking warfarin at some
oint during the study. Post-enrollment AF in the first year
as closely associated with new warfarin therapy in the
econd year (p  0.001, OR  6.6 [95% CI 3.7 to 11.9]).
Among the 1,204 patients in the MOST study who did
ot receive warfarin during the course of the study, there
ere 50 strokes. In these patients univariable analysis
howed the same variables with an association with stroke
isk as for all patients: age, NYHA functional class, prior
F, hypertension, and prior stroke or TIA. The direction
nd magnitude of the associations were similar to those in
he entire MOST study sample. In the multivariable model,
he only independent predictors of stroke were prior stroke
r TIA and age.
ISCUSSION
he major finding of this analysis of a large prospective
andomized clinical trial of patients with sick sinus syn-
rome was that baseline clinical characteristics, but not
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Stroke in Patients Paced for Sick Sinus Syndrome May 5, 2004:1617–22ode of pacing, were associated with subsequent stroke.
he clinical predictors of stroke included prior neurologic
vent (either stroke or TIA), prior systemic embolism, age,
ypertension, and NYHA functional class before pacemaker
mplantation.
ncidence of stroke in sinus node dysfunction. In the
OST study, the incidence of stroke in the first year after
mplant was 2.2% (95% CI 1.6 to 2.9). Early observational
tudies of patients with sinus node dysfunction estimated
he yearly incidence of stroke at 6% to 10% (2–5). In a
onrandomized study of 507 patients paced for sinus node
ysfunction between 1980 and 1989, the actuarial incidence
f stroke was 3% at one year and 5% at five years (16). In the
igure 1. Stroke rate in patients paced for sinus node dysfunction. K
ate-modulated pacing (VVIR) (dotted line) or dual-chamber rate-modul
able 3. Association of Baseline Variables With Stroke:
ultivariable Analysis
Variable Hazard Ratio 95% CI p Value
rior stroke or TIA 1.80 1.12–2.89 0.014
aucasian race 2.44 1.12–5.32 0.024
ypertension 1.70 1.06–2.72 0.028
rior systemic embolism 2.43 1.06–5.60 0.037
YHA CHF functional
class III or IV
1.67 1.01–2.77 0.044
DDR pacing 0.83 0.55–1.25 0.370
I  confidence interval; CHF  congestive heart failure; DDDR  dual-chamber
ate-modulated pacing; NYHA  New York Heart Association; TIA  transientwschemic attack.rst small, randomized trial of physiologic pacing in sinus
ode dysfunction, the thromboembolic event was 11.5% in
atients followed for a mean of 40 months (12).
The role of antithrombotic therapy in the prevention of
troke in patients with AF has been assessed in a number of
arge multicenter trials (10). The annual risk of stroke in the
ontrol patients ranged from 1% in those younger than 65
ears to 8.1% in those older than 75 years with more than
ne risk factor, such as hypertension, prior stroke, or
iabetes. By comparison, the annualized rate of stroke in
hose patients treated with antithrombotic therapy was
etween 1% and 1.7% (10). On the basis of these studies,
ntithrombotic therapy is now recommended as primary
revention for ischemic stroke, except in those patients who
re under age 65 years and have no risk factors (23,24).
Although patients paced for sinus node dysfunction
epresent a different population of patients than those with
rimary AF, antithrombotic therapy may nonetheless influ-
nce their risk of stroke. Therefore, one explanation for the
ow incidence of stroke in the MOST study is the higher use
f aspirin and warfarin than in earlier studies. In the MOST
tudy, a total of 72% of patients were receiving antithrom-
otic or antiplatelet therapy at the time of hospital dis-
harge: 48% of patients received aspirin and 24% received
-Meier plot of the stroke rate in patients receiving either ventricular
acing (DDDR) (solid line). CI  confidence interval.aplanarfarin. The frequency of use of these agents in early
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May 5, 2004:1617–22 Stroke in Patients Paced for Sick Sinus Syndromebservational studies of sinus node dysfunction is not
nown. In the earliest trial of physiologic versus ventricular-
ased pacing in sick sinus syndrome, Andersen and col-
eagues reported that 95 of 225 patients (42%) received
spirin while only seven of 225 (3%) received warfarin,
erhaps explaining a relatively high stroke rate (12). By
ontrast, in the Canadian Trial Of Physiologic Pacing
CTOPP), which began after the value of antithrombotic
herapy for stroke prevention was documented, 34% of
atients were taking aspirin and 11% anticoagulant drugs at
he time of randomization (10,11). Long-term use of these
gents was not reported.
mpact of AF on subsequent stroke. The association
etween AF and stroke is well established in the clinical
iterature (10). The analyses of AF and stroke risk in most
tudies, however, are confounded by the concurrent use of
ntithrombotic therapy. Therefore, a priori, one might
xpect an attenuation of the known risk of stroke in patients
hat develop AF. Indeed, 46% of the MOST study patients
ad a history of prior AF, yet history did not predict
ubsequent stroke. However, an adjusted analysis of AF
ollowing randomization as a predictor of stroke was signif-
cant: patients with AF post-randomization had a 70%
igher relative risk of stroke than patients without AF, even
fter adjustment for important clinical predictors. This
nding may suggest that the routine clinical use of anti-
hrombotic therapy in the MOST study population was
nsufficient to completely blunt the risk of AF.
nalysis of the use of warfarin in the MOST study.
here were a total of 90 strokes in the MOST study.
herapeutic anticoagulation is known to markedly reduce
he risk of stroke in patients with AF (10). Therefore, the
attern of warfarin use in our study population is a poten-
ially confounding variable when one tries to analyze risk
actors for stroke. Because the level of anticoagulation was
ot specifically recorded during the MOST study, it is
ifficult to determine whether patients were receiving war-
arin and, if they were, their level of anticoagulation at the
ime of stroke. Nonetheless, the close relationship between
arfarin use and AF in our study cohort may help explain
he low observed rate of stroke in this population. Results in
he subgroup of patients who did not receive warfarin at any
ime are consistent with the analysis of the entire group,
uggesting that the factors that affect stroke risk are similar
n warfarin and non-warfarin patients.
ole of physiologic pacing in preventing subsequent
troke. In the MOST study, physiologic pacing was not
ssociated with significantly fewer strokes. The MOST
tudy was designed to have a power of 90% to detect a
5% reduction in the combined end point of death or stroke
17). Our power to detect stroke alone was much lower.
iven the total number of events (n  90), our power to
etect as significant the difference observed for stroke alone
hazard ratio  0.82) was only 15%. In an earlier observa-
ional study, Sgarbossa et al. (16) demonstrated a strong
ssociation between ventricular-based pacing and strokehazard ratio  2.61). In the later Andersen et al. (13)
andomized trial, atrial pacing was associated with a signif-
cantly lower stroke rate compared with ventricular pacing
hen patients were followed for a mean of 5.5 years.
owever, the 22.6% rate of stroke among ventricular-paced
atients was approximately eight times higher than other
andomized trials of patients with sick sinus syndrome. In
he CTOPP study (11), where the annual rate of stroke was
ow (ventricular pacing  1.1%, physiologic pacing  1%)
nd only 42% of patients were paced for sinus node
ysfunction, no association was found. The mean follow-up
ime in the MOST study was 33 months, so it is possible
hat longer follow-up or a larger sample size may have
emonstrated a benefit of dual-chamber pacing on subse-
uent stroke. Alternatively, the high use of warfarin and
spirin in the MOST study may also have reduced any of
he beneficial effects of physiologic pacing on subsequent
troke and contributed to the low incidence of stroke. A
eta-analysis of these and other large randomized pace-
aker trials could help explore the issues.
onclusions. Baseline clinical characteristics, but not
ode of pacing, were associated with subsequent stroke in
atients paced for sinus node dysfunction. Dual-chamber
acing does not appear to decrease the incidence of stroke
ignificantly in elderly patients paced for sinus node dys-
unction. The high use of antithrombotic therapy in the
OST study, particularly in patients with AF, may have
ontributed to the low stroke rate.
eprint requests and correspondence: Dr. Arnold J. Greenspon,
efferson Heart Institute, Jefferson Medical College, 925 Chestnut
treet, Philadelphia, Pennsylvania 19107. E-mail: arnold.
reenspon@jefferson.edu.
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